Amid virtual trial craze, Science 37 earns unicorn status and a trip to Nasdaq on the back of SPAC deal

Amid virtual trial craze, Science 37 earns unicorn status and a trip to Nasdaq on the back of SPAC deal

Source: 
Endpoints
snippet: 

As the Covid-19 pandemic made conventional trials impossible for some drugmakers, more and more companies moved to decentralize their clinical studies, accelerating business for tech developers like Science 37. Leveraging that boost, the company is on the verge of a SPAC merger, landing unicorn status and its very own stock ticker.